CN102216468A - 确定产前并发症风险的方法 - Google Patents
确定产前并发症风险的方法 Download PDFInfo
- Publication number
- CN102216468A CN102216468A CN2009801105135A CN200980110513A CN102216468A CN 102216468 A CN102216468 A CN 102216468A CN 2009801105135 A CN2009801105135 A CN 2009801105135A CN 200980110513 A CN200980110513 A CN 200980110513A CN 102216468 A CN102216468 A CN 102216468A
- Authority
- CN
- China
- Prior art keywords
- risk
- preeclampsia
- plgf
- papp
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
标志物 | 对照 | FGR | PET | PIH | 早产 |
PI | 1.00(7658) | 1.08(296) | 1.31(128) | 1.07(89) | 1.06(58) |
MAP | 1.00(6584) | 1.14(296) | 1.09(120) | 1.18(82) | 1.12(56) |
标志物 | 先兆子痫 | 未受影响的 |
PlGF | -0.25** | -0.07 |
PP13(Delfia) | -0.41** | -0.09* |
PAPP-A | -0.28** | -0.17** |
MAP | -0.12 | -0.08** |
标志物 | 先兆子痫 | 未受影响的 |
PlGF | 0.06 | -0.04 |
PP13(Delfia) | 0.06 | -0.01 |
PAPP-A | 0.07 | 0.00 |
标志物 | 对照 | FGR | PET | PIH | 早产 |
MMP3 | 1.00(572) | 1.07(296) | 1.17(128) | 1.10(88) | 1.18(57) |
PlGF | 1.00(571) | 0.96(296) | 0.84(127) | 0.89(88) | 1.10(57) |
TNFR1 | 0.99(572) | 1.01(296) | 1.06(128) | 1.01(88) | 1.04(57) |
PP13(ELISA) | 1.00(312) | 0.68(170) | 0.97(77) | 0.70(48) | 0.90(21) |
PP13(Delfia) | 1.00(570) | 0.80(296) | 0.87(128) | 0.92(88) | 0.83(58) |
ADAM12 | 0.99(572) | 0.84(296) | 0.98(128) | 0.99(88) | 1.02(58) |
标志物 | 10th百分位数 | 90th百分位数 | SD |
MMP3 | 0.55 | 1.82 | 0.20 |
PlGF | 0.62 | 1.86 | 0.19 |
TNFR1 | 0.78 | 1.26 | 0.08 |
PP13(ELISA) | 0.23 | 2.74 | 0.42 |
PP13(Delfia) | 0.58 | 1.71 | 0.18 |
ADAM12 | 0.68 | 1.42 | 0.12 |
标志物 | <第1 | <第5 | <第10 | >第90 | >第95 | >第99 |
MMP3 | 0.29 | 0.45 | 0.55 | 1.82 | 2.30 | 3.25 |
高加索人 | 0.26 | 0.48 | 0.56 | 1.99 | 2.59 | 3.36 |
非高加索人 | 0.31 | 0.41 | 0.48 | 1.71 | 1.84 | 2.38 |
PlGF | 0.39 | 0.50 | 0.62 | 1.86 | 2.19 | 3.78 |
非吸烟者 | 0.40 | 0.50 | 0.62 | 1.84 | 2.15 | 3.68 |
吸烟者 | 0.71 | 0.78 | 0.88 | 2.64 | 2.76 | 4.49 |
高加索人 | 0.39 | 0.50 | 0.61 | 1.57 | 1.88 | 2.64 |
非高加索人 | 0.42 | 0.54 | 0.71 | 2.33 | 2.75 | 4.51 |
TNFR1 | 0.63 | 0.70 | 0.78 | 1.26 | 1.34 | 1.60 |
PP13(ELISA) | 0.02 | 0.04 | 0.22 | 2.66 | 4.10 | 7.92 |
非吸烟者 | 0.02 | 0.10 | 0.25 | 2.56 | 3.87 | 7.76 |
PP13(Delfia) | 0.40 | 0.49 | 0.58 | 1.72 | 2.02 | 2.75 |
非吸烟者 | 0.41 | 0.54 | 0.60 | 1.72 | 2.02 | 2.62 |
吸烟者 | 0.24 | 0.30 | 0.32 | 0.96 | 1.13 | 1.15 |
ADAM12 | 0.43 | 0.58 | 0.67 | 1.41 | 1.56 | 2.00 |
非吸烟者 | 0.45 | 0.57 | 0.68 | 1.42 | 1.57 | 1.92 |
吸烟者 | 0.63 | 0.64 | 0.65 | 1.29 | 1.34 | 1.98 |
标志物 | # | <第1 | <第5 | <第10 | >第90 | >第95 | >第99 |
MMP3 | 29 | 1 | 1 | 2 | 4 | 0 | 0 |
PlGF | 29 | 7 | 10 | 15 | 1 | 0 | 0 |
TNFR1 | 29 | 1 | 2 | 5 | 5 | 3 | 0 |
PP13ELISA | 24 | 2 | 3 | 5 | 4 | 3 | 1 |
PP13Delfia | 29 | 5 | 5 | 7 | 1 | 1 | 0 |
ADAM12 | 29 | 2 | 2 | 6 | 2 | 0 | 0 |
标志物 | # | <第1 | <第5 | <第10 | >第90 | >第95 | >第99 |
MMP3 | 22 | 0 | 1 | 2 | 4 | 3 | 1 |
PlGF | 21 | 3 | 5 | 7 | 1 | 0 | 0 |
TNFR1 | 22 | 1 | 1 | 3 | 5 | 4 | 0 |
PP13(ELISA) | 12 | 2 | 3 | 3 | 0 | 0 | 0 |
PP13(Delfia) | 22 | 2 | 3 | 8 | 0 | 0 | 0 |
ADAM12 | 22 | 1 | 4 | 5 | 1 | 1 | 0 |
标志物 | 先兆子痫 | 未受影响的 |
MMP3 | 0.12 | -0.07 |
PlGF | 0.34** | 0.27** |
TNFR1 | -0.02 | -0.04 |
PP13(ELISA) | 0.11 | 0.20** |
PP13(Delfia) | 0.38** | 0.27** |
ADAM12 | 0.49** | 0.42** |
标志物 | 先兆子痫 | 未受影响的 |
MMP3 | 0.02 | -0.06 |
PlGF | 0.08 | 0.18** |
TNFR1 | 0.05 | 0.10* |
PP13(ELISA) | 0.26* | 0.15* |
PP13(Delfia) | 0.40** | 0.32** |
ADAM12 | 0.26** | 0.21** |
结局 | PlGF | PP13 | ADAM12 |
唐氏综合征(26) | 0.56(0.19)** | 0.88(0.18) | 0.85(0.17) |
其它非整倍体性(22) | 0.54(0.17)*** | 0.55(0.22)*** | 0.69(0.11)* |
对照(83) | 0.94(0.24) | 0.99(0.19) | 1.00(0.17) |
标志物 | <第1 | <第5 | <第10 | >第90 | >第95 | >第99 |
PlGF | 0.39 | 0.50 | 0.62 | 1.86 | 2.19 | 3.78 |
非吸烟者 | 0.40 | 0.50 | 0.62 | 1.84 | 2.15 | 3.68 |
吸烟者 | 0.71 | 0.78 | 0.88 | 2.64 | 2.76 | 4.49 |
高加索人 | 0.39 | 0.50 | 0.61 | 1.57 | 1.88 | 2.64 |
非高加索人 | 0.42 | 0.54 | 0.71 | 2.33 | 2.75 | 4.51 |
Claims (35)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410206612.6A CN103969455B (zh) | 2008-01-25 | 2009-01-26 | 确定产前并发症风险的方法 |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2377608P | 2008-01-25 | 2008-01-25 | |
US61/023,776 | 2008-01-25 | ||
US2589008P | 2008-02-04 | 2008-02-04 | |
US61/025,890 | 2008-02-04 | ||
US6004808P | 2008-06-09 | 2008-06-09 | |
US61/060,048 | 2008-06-09 | ||
US6073208P | 2008-06-11 | 2008-06-11 | |
US61/060,732 | 2008-06-11 | ||
PCT/US2009/032062 WO2009094665A1 (en) | 2008-01-25 | 2009-01-26 | Methods for determining the risk of prenatal complications |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410206612.6A Division CN103969455B (zh) | 2008-01-25 | 2009-01-26 | 确定产前并发症风险的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102216468A true CN102216468A (zh) | 2011-10-12 |
CN102216468B CN102216468B (zh) | 2014-06-11 |
Family
ID=40901463
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980110513.5A Active CN102216468B (zh) | 2008-01-25 | 2009-01-26 | 确定产前并发症风险的方法 |
CN201410206612.6A Active CN103969455B (zh) | 2008-01-25 | 2009-01-26 | 确定产前并发症风险的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410206612.6A Active CN103969455B (zh) | 2008-01-25 | 2009-01-26 | 确定产前并发症风险的方法 |
Country Status (9)
Country | Link |
---|---|
US (5) | US8647832B2 (zh) |
EP (3) | EP2657697B1 (zh) |
CN (2) | CN102216468B (zh) |
AU (1) | AU2009206243B2 (zh) |
CA (2) | CA2713229C (zh) |
ES (2) | ES2523220T3 (zh) |
HK (1) | HK1162616A1 (zh) |
PL (1) | PL2245180T3 (zh) |
WO (1) | WO2009094665A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103207274A (zh) * | 2013-04-28 | 2013-07-17 | 成都中医药大学 | 一种胎儿7号染色体异常疾病的筛查试剂盒 |
CN103235142A (zh) * | 2013-04-28 | 2013-08-07 | 成都中医药大学 | 一种孕妇初次妊娠筛查试剂盒 |
CN103235133A (zh) * | 2013-04-28 | 2013-08-07 | 成都中医药大学 | 一种胎儿9号染色体异常疾病的筛查试剂盒 |
CN103278633A (zh) * | 2013-04-28 | 2013-09-04 | 成都中医药大学 | 一种孕妇流产史筛查试剂盒 |
CN104380104A (zh) * | 2012-04-24 | 2015-02-25 | 西门子医疗保健诊断公司 | 先兆子痫筛查法 |
CN105229471A (zh) * | 2013-03-15 | 2016-01-06 | 沃拉克有限公司 | 用于基于生物化学标记分析确定先兆子痫风险的系统和方法 |
CN106662590A (zh) * | 2014-05-16 | 2017-05-10 | 塞尚公司 | 早期胎盘胰岛素样肽(pro‑EPIL) |
CN108604258A (zh) * | 2016-01-20 | 2018-09-28 | 伊万基因诊断中心有限公司 | 染色体异常判断方法 |
CN111370121A (zh) * | 2020-02-21 | 2020-07-03 | 杭州市妇产科医院 | 早孕期非整倍体产前筛查标志物预测妊娠期高血压疾病的风险模型建立方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4460829B2 (ja) * | 2000-10-20 | 2010-05-12 | コモ・バイオテック・アンパルトセルスカブ | 妊娠関連血漿蛋白−a2(papp−a2) |
WO2009094665A1 (en) * | 2008-01-25 | 2009-07-30 | Perkinelmer Health Sciences, Inc. | Methods for determining the risk of prenatal complications |
US8876714B2 (en) * | 2010-02-22 | 2014-11-04 | Wallac Oy | Systems and methods for assessing risk of chromosomal disorders |
CA2819886A1 (en) | 2010-12-06 | 2012-06-14 | Pronota N.V. | Biomarkers and parameters for hypertensive disorders of pregnancy |
CA2859295A1 (en) | 2011-12-15 | 2013-06-20 | Pronota N.V. | Biomarkers and parameters for preeclampsia |
EP2890816B1 (en) * | 2012-08-30 | 2019-06-05 | Ansh Labs LLC | Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia |
WO2015009615A1 (en) * | 2013-07-15 | 2015-01-22 | Vanderbilt University | Methods for the production of collagen iv |
US10281475B2 (en) * | 2014-03-27 | 2019-05-07 | Wayne State University | Systems and methods to identify and treat subjects at risk for obstetrical complications |
CN106796241B (zh) | 2014-09-02 | 2019-07-12 | 沃拉克有限公司 | 确定先兆子痫风险的方法 |
WO2016042202A1 (en) | 2014-09-17 | 2016-03-24 | Wallac Oy | Method for determining the risk of preterm birth |
WO2016095789A1 (en) * | 2014-12-15 | 2016-06-23 | The Chinese University Of Hong Kong | Detecting bacterial taxa for predicting preterm birth after clinical intervention |
WO2016191793A1 (en) | 2015-06-02 | 2016-12-08 | Medvet Science Pty Ltd | Methods for screening for fetal trisomies |
MX2020002788A (es) | 2017-09-13 | 2020-09-14 | Progenity Inc | Biomarcadores de preeclampsia y sistemas y metodos relacionados. |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9812432D0 (en) | 1998-06-09 | 1998-08-05 | Queen Mary & Westfield College | Predictive test |
GB0026823D0 (en) | 2000-11-02 | 2000-12-20 | King S College London | Diagnosis of pre-eclampsia |
PT2308507E (pt) * | 2002-07-19 | 2015-05-11 | Beth Israel Hospital | Métodos de tratamento de pré-eclâmpsia |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
GB0317476D0 (en) * | 2003-07-25 | 2003-08-27 | Wright David E | Methods and apparatus for screening for chromosomal abnormalities |
US20060094039A1 (en) | 2004-09-20 | 2006-05-04 | Ron Rosenfeld | Diagnosis of fetal aneuploidy |
JP5009811B2 (ja) * | 2004-12-21 | 2012-08-22 | イェール ユニバーシティ | 子癇前症の検出 |
GB0600916D0 (en) | 2006-01-17 | 2006-02-22 | Perkinelmer Instr Las Inc | detecting and predicting pre-eclampsia |
WO2009094665A1 (en) * | 2008-01-25 | 2009-07-30 | Perkinelmer Health Sciences, Inc. | Methods for determining the risk of prenatal complications |
-
2009
- 2009-01-26 WO PCT/US2009/032062 patent/WO2009094665A1/en active Application Filing
- 2009-01-26 US US12/864,625 patent/US8647832B2/en active Active
- 2009-01-26 EP EP13177423.4A patent/EP2657697B1/en active Active
- 2009-01-26 ES ES09704269.1T patent/ES2523220T3/es active Active
- 2009-01-26 PL PL09704269T patent/PL2245180T3/pl unknown
- 2009-01-26 CN CN200980110513.5A patent/CN102216468B/zh active Active
- 2009-01-26 EP EP16173417.3A patent/EP3109322A1/en not_active Withdrawn
- 2009-01-26 ES ES13177423.4T patent/ES2587077T3/es active Active
- 2009-01-26 CA CA2713229A patent/CA2713229C/en active Active
- 2009-01-26 EP EP09704269.1A patent/EP2245180B1/en active Active
- 2009-01-26 AU AU2009206243A patent/AU2009206243B2/en active Active
- 2009-01-26 CA CA2967508A patent/CA2967508C/en active Active
- 2009-01-26 CN CN201410206612.6A patent/CN103969455B/zh active Active
-
2012
- 2012-04-02 HK HK12103231.9A patent/HK1162616A1/zh unknown
-
2013
- 2013-07-18 US US13/945,143 patent/US8673582B2/en active Active
- 2013-12-31 US US14/144,687 patent/US20140113319A1/en not_active Abandoned
- 2013-12-31 US US14/144,740 patent/US8932823B2/en active Active
-
2015
- 2015-11-13 US US14/941,337 patent/US20160305950A1/en not_active Abandoned
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104380104A (zh) * | 2012-04-24 | 2015-02-25 | 西门子医疗保健诊断公司 | 先兆子痫筛查法 |
CN104380104B (zh) * | 2012-04-24 | 2021-03-30 | 西门子医疗保健诊断公司 | 先兆子痫筛查法 |
CN105229471B (zh) * | 2013-03-15 | 2019-04-19 | 沃拉克有限公司 | 用于基于生物化学标记分析确定先兆子痫风险的系统和方法 |
CN105229471A (zh) * | 2013-03-15 | 2016-01-06 | 沃拉克有限公司 | 用于基于生物化学标记分析确定先兆子痫风险的系统和方法 |
CN103278633A (zh) * | 2013-04-28 | 2013-09-04 | 成都中医药大学 | 一种孕妇流产史筛查试剂盒 |
CN103235133B (zh) * | 2013-04-28 | 2014-11-19 | 成都中医药大学 | 一种胎儿9号染色体异常疾病的筛查试剂盒 |
CN103235133A (zh) * | 2013-04-28 | 2013-08-07 | 成都中医药大学 | 一种胎儿9号染色体异常疾病的筛查试剂盒 |
CN103207274A (zh) * | 2013-04-28 | 2013-07-17 | 成都中医药大学 | 一种胎儿7号染色体异常疾病的筛查试剂盒 |
CN103235142A (zh) * | 2013-04-28 | 2013-08-07 | 成都中医药大学 | 一种孕妇初次妊娠筛查试剂盒 |
CN106662590A (zh) * | 2014-05-16 | 2017-05-10 | 塞尚公司 | 早期胎盘胰岛素样肽(pro‑EPIL) |
CN108604258A (zh) * | 2016-01-20 | 2018-09-28 | 伊万基因诊断中心有限公司 | 染色体异常判断方法 |
CN108604258B (zh) * | 2016-01-20 | 2022-05-13 | 伊万基因诊断中心有限公司 | 染色体异常判断方法 |
CN111370121A (zh) * | 2020-02-21 | 2020-07-03 | 杭州市妇产科医院 | 早孕期非整倍体产前筛查标志物预测妊娠期高血压疾病的风险模型建立方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2713229C (en) | 2017-07-11 |
US20100304412A1 (en) | 2010-12-02 |
ES2587077T3 (es) | 2016-10-20 |
EP2245180A1 (en) | 2010-11-03 |
EP2245180A4 (en) | 2011-06-08 |
CA2713229A1 (en) | 2009-07-30 |
CN103969455A (zh) | 2014-08-06 |
EP3109322A1 (en) | 2016-12-28 |
EP2657697B1 (en) | 2016-06-08 |
US20160305950A1 (en) | 2016-10-20 |
US8673582B2 (en) | 2014-03-18 |
EP2657697A2 (en) | 2013-10-30 |
ES2523220T3 (es) | 2014-11-24 |
US8932823B2 (en) | 2015-01-13 |
EP2245180B1 (en) | 2014-06-18 |
US20140113320A1 (en) | 2014-04-24 |
AU2009206243B2 (en) | 2014-10-02 |
WO2009094665A1 (en) | 2009-07-30 |
CN103969455B (zh) | 2016-08-24 |
US20140113319A1 (en) | 2014-04-24 |
CA2967508A1 (en) | 2009-07-30 |
CN102216468B (zh) | 2014-06-11 |
US8647832B2 (en) | 2014-02-11 |
CA2967508C (en) | 2020-02-25 |
PL2245180T3 (pl) | 2015-03-31 |
HK1162616A1 (zh) | 2012-08-31 |
US20130344503A1 (en) | 2013-12-26 |
EP2657697A3 (en) | 2014-02-19 |
AU2009206243A1 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102216468B (zh) | 确定产前并发症风险的方法 | |
Simas et al. | Angiogenic factors for the prediction of preeclampsia in high-risk women | |
Peaceman et al. | Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial | |
Poon et al. | First‐trimester maternal factors and biomarker screening for preeclampsia | |
Akolekar et al. | Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia | |
Papaioannou et al. | Ultrasonographic prediction of early miscarriage | |
Goetzinger et al. | Development and validation of a risk factor scoring system for first-trimester prediction of preeclampsia | |
CN104749384B (zh) | 确定母体健康风险的方法 | |
Kirkegaard et al. | PAPP‐A, free β‐hCG, and early fetal growth identify two pathways leading to preterm delivery | |
EP3189336B1 (en) | Method for determining risk of pre-eclampsia | |
Kim et al. | First-trimester screening for early preeclampsia risk using maternal characteristics and estimated placental volume | |
US11255861B2 (en) | Method for determining the risk of preterm birth | |
Kosiński et al. | First trimester erythropoietin (EPO) serum concentration as a potential marker for abnormal placentation disorders. Reference values for erythropoietin (EPO) concentration at 11–13+ 6 weeks of gestation | |
AU2014259509B2 (en) | Methods for determining the risk of prenatal complications | |
Shim et al. | Prenatal sFlt-1/PlGF value for prediction of adverse neonatal outcome of isolated ultrasonic small-for-gestational-age fetus in normotensive pregnant women: A prospective cohort study | |
Karagiannis | First Trimester Prediction of the'small for Gestational Age'Fetus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1162616 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: WALLAC OY FETAL MEDICINE FOUNDATION Free format text: FORMER OWNER: WALLAC OY FETAL MEDICINE FOUNDATION NICOLAIDES KYPROS Effective date: 20140506 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140506 Address after: Massachusetts, USA Applicant after: Perkinelmer Health Sciences Inc. Applicant after: Wallac Oy Applicant after: Fetal Medicine Foundation Address before: Massachusetts, USA Applicant before: Perkinelmer Health Sciences Inc. Applicant before: Wallac Oy Applicant before: Fetal Medicine Foundation Applicant before: Kypros Nicolaides |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1162616 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170302 Address after: Finland Turku Patentee after: Wallac Oy Patentee after: Fetal Medicine Foundation Address before: Massachusetts, USA Patentee before: Perkinelmer Health Sciences Inc. Patentee before: Wallac Oy Patentee before: Fetal Medicine Foundation |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200102 Address after: Finland Turku Patentee after: Wallac Oy Address before: Finland Turku Co-patentee before: Fetal Medicine Foundation Patentee before: Wallac Oy |
|
TR01 | Transfer of patent right |